[HTML][HTML] The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma
Human hepatocellular carcinoma (HCC) is the third most common cause of cancer-related
death. Alpha-fetoprotein (AFP) is perhaps the best-defined tumor marker for HCC, and as …
death. Alpha-fetoprotein (AFP) is perhaps the best-defined tumor marker for HCC, and as …
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
Dendritic cells (DCs) are the most potent APCs, with the ability to orchestrate a repertoire of
immune responses. DCs play a pivotal role in the initiation, programming and regulation of …
immune responses. DCs play a pivotal role in the initiation, programming and regulation of …
[HTML][HTML] Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
Y Shindo, S Hazama, Y Maeda, H Matsui, M Iida… - Journal of translational …, 2014 - Springer
Background We previously reported the clinical efficacy of adoptive immunotherapy (AIT)
with dendritic cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes …
with dendritic cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes …
Long-term outcome of immunotherapy for patients with refractory pancreatic cancer
M Nakamura, J Wada, H Suzuki, M Tanaka… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Pancreatic cancer is one of the most fatal human cancers, with a 5-year
survival rate of< 5%. Although new chemotherapies have been used for pancreatic cancer …
survival rate of< 5%. Although new chemotherapies have been used for pancreatic cancer …
Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients
J Wada, A Yamasaki, S Nagai, K Yanai… - Anticancer …, 2008 - ar.iiarjournals.org
We previously showed that a combination therapy with tumor cell-pulsed monocyte-derived
dendritic cells (DCs) and activated lymphocytes was well tolerated in patients with …
dendritic cells (DCs) and activated lymphocytes was well tolerated in patients with …
[PDF][PDF] Dendritic cells as therapeutic agents against cancer
EA Eksioglu, S Eisen, V Reddy - Front Biosci, 2010 - article.imrpress.com
Introduction 3. DC Immunobiology 4. Dendritic Cell Subpopulations 5. The type1/type 2
dualism and cancer 6. Generation of DC for Therapy 7. Consideration of DC Maturation …
dualism and cancer 6. Generation of DC for Therapy 7. Consideration of DC Maturation …
Distinct effect of CD40 and TNF-signaling on the chemokine/chemokine receptor expression and function of the human monocyte-derived dendritic cells
Y Xia, J Dai, P Lu, Y Huang, Y Zhu… - Cellular & Molecular …, 2008 - nature.com
A key and limiting step in the process of human monocyte-derived dendritic cells (mDCs) for
clinical use is their in vitro maturation and in vivo migration. We previously observed that …
clinical use is their in vitro maturation and in vivo migration. We previously observed that …
In Vivo Imaging of Lymph Node Migration of MNP- and 111In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras)
C Martelli, M Borelli, L Ottobrini, V Rainone… - Molecular imaging and …, 2012 - Springer
Purpose The authors present a protocol for the in vivo evaluation, using different imaging
techniques, of lymph node (LN) homing of tumor-specific dendritic cells (DCs) in a murine …
techniques, of lymph node (LN) homing of tumor-specific dendritic cells (DCs) in a murine …
The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity
MY Park, CH Kim, HJ Sohn, ST Oh, SG Kim, TG Kim - Vaccine, 2007 - Elsevier
The gradual induction of immune responses by dendritic cell (DC) vaccination or the rapid
decrease of adoptively transferred T cells may be major limitations in complete treatment of …
decrease of adoptively transferred T cells may be major limitations in complete treatment of …
Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: A retrospective analysis
T Morisaki, T Morisaki, M Kubo, H Onishi… - Anticancer …, 2021 - ar.iiarjournals.org
Abstract Background/Aim: Neoantigens are tumor-specific antigens that emerge due to gene
mutations in tumor cells, and are highly antigenic epitopes that escape central immune …
mutations in tumor cells, and are highly antigenic epitopes that escape central immune …